PTC Therapeutics
PTCT
293 hedge funds and large institutions have $5.07B invested in PTC Therapeutics in 2025 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 101 increasing their positions, 105 reducing their positions, and 41 closing their positions.
265% more call options, than puts
Call options by funds: $50.2M | Put options by funds: $13.8M
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
34% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 41
30% more capital invested
Capital invested by funds: $3.9B → $5.07B (+$1.17B)
4% more funds holding
Funds holding: 283 → 293 (+10)
3.25% more ownership
Funds ownership: 100.83% → 104.08% (+3.3%)
4% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 105
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
+$82.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$63.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$42.2M |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$41.7M |
| 5 |
Millennium Management
New York
|
+$35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$76M |
| 2 |
Morgan Stanley
New York
|
-$38.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$29.1M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$27.3M |
| 5 |
Man Group
London,
United Kingdom
|
-$21.2M |
PTCT Hedge Fund Activity: Q3 2025 in Review
293 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2025, worth a combined $5.07B — up 30% from $3.9B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new PTCT positions and 41 closed out — a net gain of 14 holders — while 101 added to existing stakes and 105 trimmed.
The largest buyer was Jefferies Financial Group, opening a new position worth an estimated $82.5M. The largest seller was Armistice Capital, cutting an estimated $76M.
- 293 institutional investors held PTC Therapeutics (PTCT) as of Q3 2025, up from 283 in Q2 2025.
- Funds reported $5.07B of PTC Therapeutics stock for Q3 2025, up 30% quarter-over-quarter.
- 55 funds opened new PTC Therapeutics positions in Q3 2025 and 41 closed out, a net change of +14 holders.
- The largest PTC Therapeutics buyer in Q3 2025 was Jefferies Financial Group, an estimated $82.5M added.
- The largest PTC Therapeutics seller in Q3 2025 was Armistice Capital, an estimated $76M sold.
Based on aggregated 13F filings for Q3 2025.